Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
48.54
-1.05 (-2.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,653,910
Open
48.85
Bid (Size)
47.00 (10)
Ask (Size)
49.00 (1)
Prev. Close
49.59
Today's Range
48.45 - 48.85
52wk Range
42.63 - 55.72
Shares Outstanding
1,250,690,553
Dividend Yield
3.92%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
July 02, 2024
A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to proceed, with the companies needing Delaware Supreme Court approval to...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Surprise! 3 Stocks That Are Outperforming Nvidia in 2024.
July 01, 2024
There are more marketplace opportunities than just AI which is why these stocks that are outperforming Nvidia have done so well.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Performance
YTD
-2.92%
-2.92%
1 Month
-1.44%
-1.44%
3 Month
+1.76%
+1.76%
6 Month
-2.92%
-2.92%
1 Year
-9.49%
-9.49%
More News
Read More
Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
July 01, 2024
Via
Benzinga
Where Will Novavax Be in 1 Year?
June 29, 2024
Via
The Motley Fool
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
June 27, 2024
Via
Benzinga
Exposures
Product Safety
Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?
June 27, 2024
Via
InvestorPlace
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
June 26, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
June 26, 2024
Via
Benzinga
Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer
June 20, 2024
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Is It Too Late to Buy Novavax Stock?
June 14, 2024
Via
The Motley Fool
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
June 13, 2024
Via
Investor's Business Daily
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
June 12, 2024
Via
Investor's Business Daily
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge
June 12, 2024
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
June 11, 2024
Via
The Motley Fool
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
June 10, 2024
Via
Investor's Business Daily
Exposures
COVID-19
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
June 07, 2024
Via
InvestorPlace
The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash
June 07, 2024
Via
InvestorPlace
Sanofi Highlights Data From Blood Cancer Drug Sarclisa In New Diagnosed Multiple Myeloma Patients
June 04, 2024
Via
Benzinga
3 Dividend Stocks to Buy in June 2024 for Dependable Dividend Growth
June 03, 2024
Via
InvestorPlace
Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward
June 03, 2024
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Growth Stocks to Avoid Like the Plague: 3 Overpriced Picks Primed to Plummet
June 01, 2024
Via
InvestorPlace
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
May 31, 2024
Via
Benzinga
Exposures
Product Safety
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
May 31, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
May 31, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
VeeCon 2024 Speakers Announced: X CEO Linda Yaccarino, Content Creator Khaby Lame, Gary Vee Among Special Guests To Appear At Festival That Combines Business, Pop Culture, Web3
May 29, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.